Literature DB >> 9156390

Infectious complications of immunosuppressive therapy in patients with rheumatic diseases.

B H Segal1, M C Sneller.   

Abstract

Infection continues to be a significant cause of morbidity and mortality in patients with rheumatic diseases, and, consequently, early diagnosis and treatment of infection is critical to the successful medical management of these patients. The intensity of immunosuppressive therapy is the dominant risk factor for infection in this patient population. Because the manifestations of infection in patients with rheumatic diseases are highly variable, the clinician must always be vigilant about the possibility of infection even if the clinical presentation is highly suggestive of an exacerbation of the underlying disease. We have stressed a systematic and individualized approach in the diagnostic evaluation of suspected infection in these patients. The first part of the evaluation involves forming a list of the most likely pathogens based on a detailed history and physical examination and the intensity and type of immunosuppressive therapy the patient is receiving. The physician must then formulate a plan designed to establish a diagnosis expeditiously and with the least morbidity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9156390     DOI: 10.1016/s0889-857x(05)70327-6

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  16 in total

Review 1.  Pulmonary aspergillosis: clinical presentation, diagnostic tests, management and complications.

Authors:  Rami Sherif; Brahm H Segal
Journal:  Curr Opin Pulm Med       Date:  2010-05       Impact factor: 3.155

2.  Safety of extended treatment with anakinra in patients with rheumatoid arthritis.

Authors:  R M Fleischmann; J Tesser; M H Schiff; J Schechtman; G-R Burmester; R Bennett; D Modafferi; L Zhou; D Bell; B Appleton
Journal:  Ann Rheum Dis       Date:  2006-01-05       Impact factor: 19.103

Review 3.  [The radiology of opportunistic pneumonias. I: Epidemiological, laboratory and clinical background].

Authors:  S Tuengerthal
Journal:  Radiologe       Date:  2005-04       Impact factor: 0.635

4.  High association of mycobacterial infections with polymyositis in a non-endemic country for tuberculosis.

Authors:  Antti Airio; Markku Kauppi; Hannu Kautiainen; Markku Hakala; Vuokko Kinnula
Journal:  Ann Rheum Dis       Date:  2007-10       Impact factor: 19.103

5.  Serious infections under treatment with TNF-alpha antagonists compared to traditional DMARDs in patients with rheumatoid arthritis.

Authors:  N Inanc; H Direskeneli
Journal:  Rheumatol Int       Date:  2006-08-02       Impact factor: 2.631

6.  Correlation between systemic lupus erythematosus and cytomegalovirus infection detected by different methods.

Authors:  Jing Chen; Huidi Zhang; Peirong Chen; Qiaoai Lin; Xiaochun Zhu; Lifang Zhang; Xiangyang Xue
Journal:  Clin Rheumatol       Date:  2015-03-10       Impact factor: 2.980

7.  Infection in children with lupus nephritis receiving pulse and oral cyclophosphamide therapy.

Authors:  Sauwalak Opastirakul; Wattana Chartapisak
Journal:  Pediatr Nephrol       Date:  2005-08-24       Impact factor: 3.714

8.  Levels of serum procalcitonin and C-reactive protein for evaluating pulmonary bacterial infection in patients with lupus erythematosus.

Authors:  Jing Gao; Lei Zhang; Xin Zhang; Shi-Long Zhao; Sheng-Yun Liu; Li-Hua Xing
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-10-18

9.  Statin, calcium channel blocker and Beta blocker therapy may decrease the incidence of tuberculosis infection in elderly Taiwanese patients with type 2 diabetes.

Authors:  Mei-Yueh Lee; Kun-Der Lin; Wei-Hao Hsu; Hsiu-Ling Chang; Yi-Hsin Yang; Pi-Jung Hsiao; Shyi-Jang Shin
Journal:  Int J Mol Sci       Date:  2015-05-18       Impact factor: 5.923

10.  Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus.

Authors:  Kiyoshi Migita; Yukihiro Akeda; Manabu Akazawa; Shigeto Tohma; Fuminori Hirano; Haruko Ideguchi; Ryutaro Matsumura; Eiichi Suematsu; Tomoya Miyamura; Shunsuke Mori; Takahiro Fukui; Yasumori Izumi; Nozomi Iwanaga; Hiroshi Tsutani; Kouichirou Saisyo; Takao Yamanaka; Shiro Ohshima; Takao Sugiyama; Yojiro Kawabe; Masao Katayama; Yasuo Suenaga; Akira Okamoto; Hisaji Ohshima; Yasumasa Okada; Kenji Ichikawa; Shigeru Yoshizawa; Kenji Kawakami; Toshihiro Matsui; Hiroshi Furukawa; Kazunori Oishi
Journal:  Arthritis Res Ther       Date:  2015-06-03       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.